Submission Procedures

All IIS applications are processed as follows:
 

  • 1. Applicant reviews the entire content of the eisaigrants.com IIS website.
  • 2. Applicant selects the product or investigational compound that will be the subject
        of the IIS research.
  • 3. Applicant completes the Eisai Investigator Initiated Studies (IIS) Application and
        submits to the IIS Coordinator
  • 4. IIS Coordinator ensures that the Applicant has correctly completed all components
        of the application and then forwards the Request to the applicable product or
        investigational compound IIS Committee for review and approval
  • 5. IIS Coordinator notifies Applicant whether grant has been approved or
        denied. Approval is on a conditional basis, subject to the execution of an Agreement,
        in a form acceptable to Eisai.
  • 6. If application is approved, the IIS Coordinator oversees the process of generating
        a written agreement between Eisai and the applicable requesting organization.
  • 7. Upon contract execution, IIS Coordinator arranges for issuance of payment(s)
        and/or drug supply as per contract requirements.
  • 8. ALL MATTERS RELATING TO INVESTIGATOR INITIATED STUDIES (IIS) MUST
        BE DIRECTED TO AND HANDLED BY THE IIS COORDINATOR.
     

To begin your application, please select the product for which you are requesting IIS support:

 

BANZEL® (rufinamide)

 

BELVIQ® (lorcaserin HCI) (CIV)

 

FYCOMPA® (perampanel) tablets

 

HALAVEN® (eribulin mesylate) Injection

 

LENVIMA (lenvatinib) capsules